

From: [REDACTED]
Sent: Wed Jun 21 2006 14:12:50 EDT
To: [REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]ratna.lingamancni/cambridge/biogen@biogenidec; [REDACTED]
[REDACTED];tammy.sarnelli/cambridge/biogen@biogenidec;gilmore
o'neill/cambridge/biogen@biogenidec;minhua.yang/cambridge/biogen@biogenidec;cara
lansden/cambridge/biogen@biogenidec; [REDACTED]
CC: [REDACTED]
MoodStamp: FYI
Subject: BG12 Protocol Review

Hello BG12 CDT Members,
This message is to notify you of next week's review of the two (draft) BG12 Phase 3 clinical protocols: 109MS301 (monotherapy) and 109MS302 (3-arm, reference comparator). The plan is to distribute the protocols by EOB (EST) on Monday, 26Jun06. Comments are due to [REDACTED] by EOB on Thursday, 29June06.

Remember our goal is to complete these protocols for the EOP2 submission package (due by 13July06) - which means our timeline for protocol production is condensed. Please be as timely as possible with your review and comments.

If there is any change to this schedule, I will notify you ASAP.
Thank you for your time and attention.
Regards,

